Trabectedin: A Review of its Use in the Management of Soft Tissue Sarcoma and Ovarian Cancer

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660 · see citing works

Cancer Statistics, 2007

Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439 · see citing works

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

Armstrong, D. K., Bundy, B. N., Wenzel, L. B., Huang, H. Q., Baergen, R. N., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,626 · see citing works

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial

Parmar, M., Ledermann, J. A., Colombo, N., du Bois, A., Jf, D., Kristensen, G. B., Wheeler, S., Swart, A. M., Qian, W., Torri, V., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13718-x · Cited by 1,180 · see citing works

Soft-Tissue Sarcomas in Adults

Clark, M. A., Fisher, C., Judson, I. R., & Thomas, J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041866 · Cited by 911 · see citing works

Soft Tissue Sarcomas

Cormier, J. N., & Pollock, R. E. (2004) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.2.94 · Cited by 839 · see citing works

Marine natural products as anticancer drugs

Simmons, T. L., Andrianasolo, E., McPhail, K., Flatt, P., & Gerwick, W. H. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.333.4.2 · Cited by 597 · see citing works

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study

Grosso, F., Jones, R. L., Demetri, G. D., Judson, I. R., Blay, J., Cesne, A. L., Sanfilippo, R. G., Casieri, P., Collini, P., Dileo, P., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70175-4 · Cited by 490 · see citing works

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas

Glabbeke, M. M. V., Verweij, J., Judson, I. R., & Nielsen, O. S. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00398-7 · Cited by 462 · see citing works

Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial

Cesne, A. L., Blay, J., Judson, I. R., van Oosterom, A., Verweij, J., Radford, J. A., Lorigan, P. C., Rodenhuis, S., Ray-Coquard, I., Bonvalot, S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.180 · Cited by 458 · see citing works

Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy

García‐Carbonero, R., Supko, J., Manola, J. B., Seiden, M. V., Harmon, D. C., Ryan, D. P., Quigley, M., Merriam, P. A., Canniff, J., Goss, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.098 · Cited by 331 · see citing works

Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients

Yovine, A. J., Riofrio, M., Blay, J., Brain, E. G. C., Alexandre, J., Kahatt, C. M., Taamma, A., Jimeno, J. M., Martin, C., Salhi, Y., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.210 · Cited by 310 · see citing works

Anti-inflammatory Properties of the Novel Antitumor Agent Yondelis (Trabectedin): Inhibition of Macrophage Differentiation and Cytokine Production

Allavena, P., Signorelli, M., Chieppa, M., Erba, E., Bianchi, G., Marchesi, F., Olimpio, C. O., Bonardi, C., Garbi, A., Lissoni, A. A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4037 · Cited by 286 · see citing works

Diagnosis and Management of Epithelial Ovarian Cancer

Bhoola, S. M., & Hoskins, W. J. (2006) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000220516.34053.48 · Cited by 205 · see citing works

Current Management Strategies for Ovarian Cancer

Aletti, G. D., Gallenberg, M. M., Cliby, W. A., Jatoi, A., & Hartmann, L. C. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.6.751 · Cited by 196 · see citing works

Ecteinascidin-743 (ET-743) for Chemotherapy-Naive Patients With Advanced Soft Tissue Sarcomas: Multicenter Phase II and Pharmacokinetic Study

García‐Carbonero, R., Supko, J. G., Maki, R. G., Manola, J. B., Ryan, D. P., Harmon, D. C., Puchalski, T. A., Goss, G., Seiden, M. V., Waxman, A. J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.028 · Cited by 191 · see citing works

Cross-Talk between Nucleotide Excision and Homologous Recombination DNA Repair Pathways in the Mechanism of Action of Antitumor Trabectedin

Herrero, A. B., Martı́n-Castellanos, C., Marco, E., Gago, F., & Moreno, S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0179 · Cited by 172 · see citing works

Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails

Sessa, C., de Braud, F., Perotti, A., Bauer, J. A., Curigliano, G., Noberasco, C., Zanaboni, F., Gianni, L., Marsoni, S., Jimeno, J. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.032 · Cited by 162 · see citing works

In vitro antitumor activity of the novel marine agent, Ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients

Izbicka, E., Lawrence, R., Raymond, É., Eckhardt, G., Faircloth, G. T., Jimeno, J. M., Clark, G. M., & VonHoff, D. D. (1998) · Annals of Oncology · doi:10.1023/a:1008224322396 · Cited by 137 · see citing works

Management of Platinum-Sensitive Recurrent Ovarian Cancer

Pfisterer, J., & Ledermann, J. A. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.03.012 · Cited by 119 · see citing works

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma

Laverdière, C., Kolb, E. A., Supko, J. G., Gorlick, R. G., Meyers, P. A., Maki, R. G., Wexler, L. H., Demetri, G. D., Healey, J. H., Huvos, A. G., et al. (2003) · Cancer · doi:10.1002/cncr.11563 · Cited by 97 · see citing works

Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells.

Takahashi, N., Li, W. W., Banerjee, D., Scotto, K. W., & Bertino, J. R. (2001) · PubMed · Cited by 96 · see citing works

Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent.

Li, W., Takahashi, N., Jhanwar, S. C., Cordon‐Cardo, C., Elisseyeff, Y., Jimeno, J. A., Faircloth, G. T., & Bertino, J. R. (2001) · PubMed · Cited by 93 · see citing works

Principles and practice of intraperitoneal chemotherapy for ovarian cancer

Fujiwara, K., Armstrong, D. K., Morgan, M. A., & Markman, M. M. (2007) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.00809.x · Cited by 91 · see citing works

The combination of yondelis and cisplatin is synergistic against human tumor xenografts

D’Incalci, M., Colombo, T., Ubezio, P., Nicoletti, I., Giavazzi, R., Erba, E., Ferrarese, L., Meco, D., Riccardi, R., Sessa, C., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00490-8 · Cited by 90 · see citing works

Ecteinascidin-743 inhibits activated but not constitutive transcription.

Friedman, D., Hu, Z., Kolb, E. A., Gorfajn, B., & Scotto, K. W. (2002) · PubMed · Cited by 89 · see citing works

The Management of Recurrent Ovarian Cancer

Bukowski, R. M., Ozols, R. F., & Markman, M. M. (2007) · Seminars in Oncology · doi:10.1053/j.seminoncol.2007.03.012 · Cited by 87 · see citing works

A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

Zelek, L. H., Yovine, A. J., Brain, E. G. C., Turpin, F., Taamma, A., Riofrio, M., Spielmann, M., Jimeno, J. M., & Misset, J. L. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603142 · Cited by 86 · see citing works

Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma

Grosso, F., Dileo, P., Sanfilippo, R. G., Stacchiotti, S., Bertulli, R., Piovesan, C., Jimeno, J. M., D’Incalci, M., Gescher, A. J., & Casali, P. G. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.02.010 · Cited by 86 · see citing works

Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.

van Kesteren, C., Cvitkovic, E., Taamma, A., Lázaro, L. L., Jimeno, J. M., Guzmán, C., t, R. A. A. M., Schellens, J. H. M., Misset, J. L., Brain, E. G. C., et al. (2000) · PubMed · Cited by 79 · see citing works

Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies

Riccardi, R., Meco, D., Colombo, T., Ubezio, P., Zucchetti, M., Zaffaroni, M., Riccardi, A., Faircloth, G. T., Jose, J., & D’Incalci, M. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0636-6 · Cited by 77 · see citing works

A Phase I and Pharmacokinetic Study of Ecteinascidin-743 (Yondelis) in Children with Refractory Solid Tumors. A Children's Oncology Group Study

Lau, L. M. S., Supko, J., Blaney, S. M., Hershon, L., Seibel, N. L., Krailo, M., Qu, W., Malkin, D. M., Jimeno, J. M., Bernstein, M. L., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.672.11.2 · Cited by 66 · see citing works

ET-743: a novel agent with activity in soft-tissue sarcomas

Fayette, J., Ray-Coquard, I. L., Alberti, L., Boyle, H. J., Méeus, P., Decouvelaere, A., Thiesse, P., Sunyach, M., Ranchère‐Vince, D., & Blay, J. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000228740.70379.3f · Cited by 66 · see citing works

Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat.

Donald, S., Verschoyle, R. D., Greaves, P., Gant, T. W., Colombo, T., Zaffaroni, M., Frapolli, R., Zucchetti, M., D’Incalci, M., Meco, D., et al. (2003) · PubMed · Cited by 64 · see citing works

Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity

Puchalski, T. A., Ryan, D. P., García‐Carbonero, R., Demetri, G. D., Butkiewicz, L., Harmon, D. C., Seiden, M. V., Maki, R. G., Lázaro, L. L., Jimeno, J. M., et al. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0498-3 · Cited by 63 · see citing works

A phase II study of ET-743/trabectedin (`Yondelis') for patients with advanced gastrointestinal stromal tumours

Blay, J., Cesne, A. L., Verweij, J., Scurr, M. R., Seynaeve, C., Bonvalot, S., Hogendoorn, P. C. W., Jimeno, J. M., Evrard, V., Glabbeke, M. M. V., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.02.005 · Cited by 52 · see citing works

Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.

Scotlandi, K., Perdichizzi, S., Manara, M. C., Serra, M., Benini, S., Cerisano, V., Strammiello, R., Mercuri, M., Reverter‐Branchat, G., Faircloth, G. T., et al. (2002) · PubMed · Cited by 49 · see citing works

In vitro interaction between Ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects

Simoens, C., Korst, A. E. C., Pooter, C. M. J. D., Lambrechts, H. A. J., Pattyn, G. G. O., Faircloth, G. T., Lardon, F., & Vermorken, J. B. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601431 · Cited by 41 · see citing works

Selective Effects of the Anticancer Drug Yondelis (ET-743) on Cell-Cycle Promoters

Minuzzo, M., Ceribelli, M., Pitarque, M., Borrelli, S., Erba, E., diSilvio, A., D’Incalci, M., & Mantovani, R. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.013615 · Cited by 41 · see citing works

Recent Developments in Salvage Chemotherapy for Patients with Metastatic Soft Tissue Sarcoma

Hartmann, J., & PATEL, S. R. (2005) · Drugs · doi:10.2165/00003495-200565020-00002 · Cited by 38 · see citing works

The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71

Manara, M. C., Perdichizzi, S., Serra, M., Pierini, R., Benini, S., Hattinger, C. M., Astolfi, A., Bagnati, R., D’Incalci, M., Picci, P., et al. (2005) · International Journal of Oncology · doi:10.3892/ijo.27.6.1605 · Cited by 37 · see citing works

In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction

Brandon, E. F. A., Meijerman, I., Klijn, J. S., den Arend, D., Sparidans, R. W., Lázaro, L. L., Beijnen, J. H., & Schellens, J. H. M. (2005) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000180121.16407.38 · Cited by 36 · see citing works

In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis®, Trabectidin®), a novel marine anti-cancer drug

Brandon, E. F. A., Sparidans, R. W., Guijt, K.-J., Löwenthal, S., Meijerman, I., Beijnen, J. H., & Schellens, J. H. M. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-4538-9 · Cited by 36 · see citing works

Further Insight into the DNA Recognition Mechanism of Trabectedin from the Differential Affinity of Its Demethylated Analogue Ecteinascidin ET729 for the Triplet DNA Binding Site CGA

Marco, E., David‐Cordonnier, M., Bailly, C., Cuevas, C., & Gago, F. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060640y · Cited by 35 · see citing works

Ecteinascidin-743 drug resistance in sarcoma cells: transcriptional and cellular alterations

Shao, L., Kasanov, J., Hornicek, F. J., Morii, T., Fondren, G., & Weissbach, L. (2003) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.08.033 · Cited by 29 · see citing works

Metabolism of trabectedin (ET-743, Yondelis™) in patients with advanced cancer

Beumer, J. H., Rademaker-Lakhai, J. M., Rosing, H., Hillebrand, M. J. X., Bosch, T. M., Lázaro, L. L., Schellens, J. H. M., & Beijnen, J. H. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0342-2 · Cited by 29 · see citing works

Treatment of patients with advanced soft tissue sarcoma: disappointment or challenge?

Kasper, B., Gil, T., & Awada, A. H. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32812143ef · Cited by 25 · see citing works

Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft

Riccardi, A., Meco, D., Ubezio, P., Mazzarella, G., Marabese, M., Faircloth, G. T., Jimeno, J. M., D’Incalci, M., & Riccardi, R. (2005) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000172837.67766.6a · Cited by 25 · see citing works

Metastatic Soft Tissue Sarcoma in Adults

Nielsen, O. S., Blay, J., Judson, I. R., Glabbeke, M. M. V., Verweij, J., & van Oosterom, A. T. (2003) · American Journal of Cancer · doi:10.2165/00024669-200302030-00005 · Cited by 21 · see citing works

Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743

Marchini, S., Marrazzo, E., Bonomi, R., Chiorino, G., Zaffaroni, M., Weissbach, L., Hornicek, F. J., Broggini, M., Faircloth, G. T., & D’Incalci, M. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.10.021 · Cited by 21 · see citing works

Trabectedin (ET-743, Yondelis™) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype

Beumer, J. H., Buckle, T., Ouwehand, M., Franke, N. E. F., Lázaro, L. L., Schellens, J. H. M., Beijnen, J. H., & van Tellingen, O. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-7773-9 · Cited by 18 · see citing works

Soft Tissue Sarcoma

Goldberg, B. R. (2007) · Orthopaedic Nursing · doi:10.1097/00006416-200701000-00003 · Cited by 10 · see citing works

Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Leyvraz, S. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm046 · Cited by 7 · see citing works

7512 POSTER Assessing the clinical impact of trabectedin in patients with leiomyosarcomas or liposarcomas (L-sarcomas) progressing despite prior conventional chemotherapy: clinical benefit rate, growth modulation index and tumor variation as parameters of treatment effect in a randomised international trial of two trabectedin dosing regimens

Cesne, A. L., von Mehren, M., Chawla, S., Blay, J., Schuetze, S. M., Nieto, A., Gomez, J., Santabarbara, P., Izquierdo, M. A., & Demetri, G. D. (2007) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(07)71489-1 · Cited by 4 · see citing works

7517 POSTER Clinical tolerability of trabectedin administered by two different schedules (weekly for 3 of 4 weeks vs q3 weeks) in patients with advanced/metastatic liposarcoma or leiomyosarcoma (L-sarcomas) progressing despite prior treatment with at least anthracycline and ifosfamide

Chawla, S., Casali, P. G., von Mehren, M., Cesne, A. L., Blay, J., Lebedinsky, C. A., Alfaro, V., Elsayed, Y. A., Michiels, B., & Demetri, G. D. (2007) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(07)71494-5 · Cited by 3 · see citing works

Epithelial ovarian carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Vasey, P. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm017 · Cited by 3 · see citing works

7500 ORAL Impact of independent review on efficacy outcomes in a randomised multicenter trial of trabectedin given by two dosing regimens in patients (pts) with progressing leiomyosarcomas or liposarcomas (L-sarcomas)

Demetri, G. D., Schuetze, S. M., Cesne, A. L., Chawla, S., Casali, P. G., Gomez, J., Nieto, A., Elsayed, Y. A., Izquierdo, M. A., & Blay, J. (2007) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(07)71477-5 · Cited by 2 · see citing works

Natural products to drugs: natural product-derived compounds in clinical trials

Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,073 · see citing works

Natural compounds for cancer treatment and prevention

Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.017 · Cited by 780 · see citing works

Marine Bioactives as Functional Food Ingredients: Potential to Reduce the Incidence of Chronic Diseases

Lordan, S., Ross, R. P., & Stanton, C. (2011) · Marine Drugs · doi:10.3390/md9061056 · Cited by 756 · see citing works

Marine Natural Products: A Source of Novel Anticancer Drugs

Khalifa, S. A. M., Elias, N., Farag, M. A., Chen, L., Saeed, A., Hegazy, M.-E. F., Moustafa, M. S., Abd El-Wahed, A., Al-Mousawi, S. M., Musharraf, S. G., et al. (2019) · Marine Drugs · doi:10.3390/md17090491 · Cited by 555 · see citing works

Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

Demetri, G. D., Chawla, S. P., von Mehren, M., Ritch, P. S., Baker, L. H., Blay, J., Hande, K. R., Keohan, M. L., Samuels, B. L., Schuetze, S. M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.0088 · Cited by 537 · see citing works

Marine Bioactive Compounds and Their Health Benefits: A Review

Hamed, I., Özogul, F., Özogul, Y., & Regenstein, J. M. (2015) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12136 · Cited by 444 · see citing works

Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer

Monk, B. J., Herzog, T. J., Kaye, S. B., Krasner, C. N., Vermorken, J. B., Muggia, F. M., Pujade-Lauraine, E., Lisyanskaya, A. S., Makhson, A. N., Rolski, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4037 · Cited by 395 · see citing works

Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 202 · see citing works

Marine natural product drug discovery: Leads for treatment of inflammation, cancer, infections, and neurological disorders

Villa, F. A., & Gerwick, L. G. (2010) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923970903296136 · Cited by 155 · see citing works

Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives

Mabuchi, S., Sugiyama, T., & Kimura, T. (2016) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2016.27.e31 · Cited by 150 · see citing works

Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma

Gronchi, A., Bui, B., Bonvalot, S., Pilotti, S., Ferrari, S., Hohenberger, P., Hohl, R. J., Demetri, G. D., Cesne, A. L., Lardelli, P., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr265 · Cited by 149 · see citing works

Ready for a comeback of natural products in oncology

Bailly, C. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.12.013 · Cited by 120 · see citing works

DNA minor groove binders: Back in the groove

Cai, X., Gray, P. J., & Hoff, D. D. V. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.02.004 · Cited by 116 · see citing works

A phase 2 study of temsirolimus (CCI‐779) in patients with soft tissue sarcomas

Okuno, S. H., Bailey, H. H., Mahoney, M. R., Adkins, D. R., Maples, W. J., Fitch, T. R., Ettinger, D. S., Erlichman, C., & Sarkaria, J. N. (2011) · Cancer · doi:10.1002/cncr.25928 · Cited by 83 · see citing works

Drug-induced hepatotoxicity in cancer patients - implication for treatment

Vincenzi, B., Armento, G., Ceruso, M. S., Catania, G., Leakos, M., Santini, D., Minotti, G., & Tonini, G. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1194824 · Cited by 81 · see citing works

A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials

Cesne, A. L., Yovine, A. J., Blay, J., Delaloge, S., Maki, R. G., Misset, J. L., Frontelo, P., Nieto, A., Jiao, J. J., & Demetri, G. D. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9662-0 · Cited by 78 · see citing works

Trabectedin

Carter, N. J., & Keam, S. J. (2010) · Drugs · doi:10.2165/11202860-000000000-00000 · Cited by 74 · see citing works

Role of chemotherapy in the management of soft tissue sarcomas

Krikelis, D., & Judson, I. R. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.176 · Cited by 72 · see citing works

Marine Natural Products with P-Glycoprotein Inhibitor Properties

Lopéz, D., & Martínez‐Luis, S. (2014) · Marine Drugs · doi:10.3390/md12010525 · Cited by 71 · see citing works

Current Status on Marine Products with Reversal Effect on Cancer Multidrug Resistance

Abraham, I., Sayed, K. A. E., Chen, Z., & Guo, H. (2012) · Marine Drugs · doi:10.3390/md10102312 · Cited by 68 · see citing works

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer

del Campo, J. M., Roszak, A., Bidziński, M., Ciuleanu, T., Högberg, T., Wojtukiewicz, M. Z., Poveda, A. M., Boman, K., Westermann, A. M., & Lebedinsky, C. A. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp198 · Cited by 65 · see citing works

Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies

Mantia-Smaldone, Edwards, & Vlad, A. (2010) · Cancer Management and Research · doi:10.2147/cmar.s8759 · Cited by 63 · see citing works

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval

Kaye, S. B., Colombo, N., Monk, B. J., Tjulandin, S., Kong, B., Roy, M., Chan, S. Y. T., Filipczyk−Cisarż, E., Hagberg, H., Vergote, I. B., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq353 · Cited by 60 · see citing works

Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma

Schöffski, P., Dumez, H., Wolter, P., Stefan, C., Woźniak, A., Jimeno, J. M., & van Oosterom, A. T. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.9.1609 · Cited by 58 · see citing works

Screening for antibacterial and antifungal activities in marine benthic invertebrates from northern Norway

Tadesse, M., Gulliksen, B., Strøm, M. B., Styrvold, O. B., & Haug, T. (2008) · Journal of Invertebrate Pathology · doi:10.1016/j.jip.2008.06.009 · Cited by 52 · see citing works

The Role of Macrophage/B-Cell Interactions in the Pathophysiology of B-Cell Lymphomas

Pham, L. V., Pogue, E., & Ford, R. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00147 · Cited by 47 · see citing works

Biosynthesis of 3-Hydroxy-5-Methyl-O-Methyltyrosine in the Saframycin/Safracin Biosynthetic Pathway

Fu, C.-Y. (2008) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.0808.484 · Cited by 45 · see citing works

Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma

Sanctis, R. D., Marrari, A., Marchetti, S., Mussi, C., Balzarini, L., Lutman, R. F., Daolio, P. A., Bastoni, S., Bertuzzi, A. F., Quagliuolo, V., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s92395 · Cited by 41 · see citing works

Natural Products in Drug Discovery: Impacts and Opportunities — An Assessment

Brahmachari, G. (2011) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814335386_0001 · Cited by 42 · see citing works

Thioholgamide A, a New Anti-Proliferative Anti-Tumor Agent, Modulates Macrophage Polarization and Metabolism

Dahlem, C., Siow, W. X., Lopatniuk, M., Tse, W. K. F., Kessler, S. M., Kirsch, S. H., Hoppstädter, J., Vollmar, A. M., Müller, R., Luzhetskyy, A. N., et al. (2020) · Cancers · doi:10.3390/cancers12051288 · Cited by 39 · see citing works

Down-regulation of the Nucleotide Excision Repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells

Sabatino, M. A., Marabese, M., Ganzinelli, M., Caiola, E., Geroni, C., & Broggini, M. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-259 · Cited by 38 · see citing works

The Activity of Trabectedin As a Single Agent or in Combination with Everolimus for Clear Cell Carcinoma of the Ovary

Mabuchi, S., Hisamatsu, T., Kawase, C., Hayashi, M., Sawada, K., Mimura, K., Takahashi, K., Takahashi, T., Kurachi, H., & Kimura, T. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2987 · Cited by 37 · see citing works

Molecular mechanisms of action of Trehalose in cancer: A comprehensive review

Chaitanya, N. S. N., Devi, A., Sahu, S., & Alugoju, P. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118968 · Cited by 37 · see citing works

Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary

Takahashi, R., Mabuchi, S., Kawano, M., Sasano, T., Matsumoto, Y., Kuroda, H., Kozasa, K., Hashimoto, K., Sawada, K., & Kimura, T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151050 · Cited by 37 · see citing works

Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum

Massutí, B., Cobo, M., Camps, C., Dómine, M., Provencio, M., Alberola, V., Viñolas, N., Rosell, R., Tarón, M., Gutiérrez, V., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.12.002 · Cited by 31 · see citing works

Rubrolide R: a new furanone metabolite from the ascidianSynoicumof the Indian Ocean

Smitha, D., Muthyala, M. K. K., Hechhu, R., & Rao, D. V. G. L. N. (2013) · Natural Product Research · doi:10.1080/14786419.2013.827194 · Cited by 29 · see citing works

A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin

Grosso, F., D’Incalci, M., Cartoafa, M., Nieto, A., Fernández‐Teruel, C., Alfaro, V., Lardelli, P., Roy, E., Gómez, J., Kahatt, C. M., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1864-4 · Cited by 29 · see citing works

Directed (R)‐ or (S)‐Selective Dynamic Kinetic Enzymatic Hydrolysis of 1,2,3,4‐Tetrahydroisoquinoline‐1‐carboxylic Esters

Paál, T. A., Liljeblad, A., Kanerva, L. T., Forró, E., & Fülöp, F. (2008) · European Journal of Organic Chemistry · doi:10.1002/ejoc.200800789 · Cited by 29 · see citing works

Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies

Forouzesh, B., Hidalgo, M. M., Chu, Q., Mita, A. C., Mita, M. M., Schwartz, G. H., Jimeno, J. M., Gómez, J., Alfaro, V., Lebedinsky, C. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2889 · Cited by 28 · see citing works

Structural and Biological Insights into the Hot‐Spot Marine Natural Products Reported from 2012 to 2021

Liu, M.-Y., Zhang, X., & Li, G. (2022) · Chinese Journal of Chemistry · doi:10.1002/cjoc.202200129 · Cited by 27 · see citing works

Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis

Lebedinsky, C. A., Gómez, J., Park, Y. C., Nieto, A., Soto-Matos, A., Parekh, T. V., Alfaro, V., Roy, E., Lardelli, P., & Kahatt, C. M. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1614-z · Cited by 27 · see citing works

New emerging drugs targeting the genomic integrity and replication machinery in ovarian cancer

Brüning, A., & Mylonas, I. G. (2010) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-010-1757-x · Cited by 26 · see citing works

The Role of Trabectedin in Soft Tissue Sarcoma

Nakamura, T., & Sudo, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.777872 · Cited by 26 · see citing works

Trabectedin in Cancers: Mechanisms and Clinical Applications

Wang, J., Wang, P., Zeng, Z., Lin, C., Lin, Y., Cao, D., Ma, W., Xu, W., Xiang, Q., Luo, L., et al. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220526125806 · Cited by 24 · see citing works

Phase I and Pharmacokinetic Study of Sequential Paclitaxel and Trabectedin Every 2 Weeks in Patients with Advanced Solid Tumors

Chu, Q., Mita, A. C., Forouzesh, B., Tolcher, A. W., Schwartz, G. K., Nieto, A., Soto-Matos, A., Alfaro, V., Lebedinsky, C. A., & Rowinsky, E. K. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0062 · Cited by 24 · see citing works

In vitro studies on the metabolism of trabectedin (YONDELIS®) in monkey and man, including human CYP reaction phenotyping

Vermeir, M., Hemeryck, A., Cuyckens, F., Francesch, A., Bockx, M., Houdt, J. V., Steemans, K., Mannens, G., Avilés, P., & Coster, R. D. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.02.020 · Cited by 23 · see citing works

Extending platinum-free interval in partially platinum-sensitive recurrent ovarian cancer by a non-platinum regimen: Its possible clinical significance

Chuang, Y.-T., & Chang, C. (2012) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2012.07.003 · Cited by 22 · see citing works

To Market, To Market — 2007

Hegde, S. G., & Schmidt, M. A. (2008) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)00025-0 · Cited by 21 · see citing works

Current Approach to Pediatric Soft Tissue Sarcomas

Merchant, M. S., & Mackall, C. L. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0160 · Cited by 21 · see citing works

Recent Advancement in Anticancer Compounds from Marine Organisms: Approval, Use and Bioinformatic Approaches to Predict New Targets

Santaniello, G., Nebbioso, A., Altucci, L., & Conte, M. (2022) · Marine Drugs · doi:10.3390/md21010024 · Cited by 20 · see citing works

Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines

Duan, Z., Choy, E., Jimeno, J. M., Cuevas, C., Mankin, H. J., & Hornicek, F. J. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0843-2 · Cited by 20 · see citing works

Macrolactone Nuiapolide, Isolated from a Hawaiian Marine Cyanobacterium, Exhibits Anti-Chemotactic Activity

Mori, S., Williams, H. H., Cagle, D., Karanovich, K., Horgen, F. D., Smith, R., & Watanabe, C. M. H. (2015) · Marine Drugs · doi:10.3390/md13106274 · Cited by 19 · see citing works

Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response

Colado, E., Paíno, T., Maiso, P., Ocio, E. M., Chen, X., Álvarez-Fernández, S., Gutierrez, N. C., Martín, J., Flores-Montero, J. A., San‐Segundo, L., et al. (2011) · Haematologica · doi:10.3324/haematol.2010.036400 · Cited by 17 · see citing works

Trabectedin for Metastatic Soft Tissue Sarcoma: A Retrospective Single Center Analysis

Schmitt, T., Keller, E. C., Dietrich, S., Wuchter, P., Ho, A. D., & Egerer, G. (2010) · Marine Drugs · doi:10.3390/md8102647 · Cited by 17 · see citing works

Drug Repurposing of FDA Compounds against α-Glucosidase for the Treatment of Type 2 Diabetes: Insights from Molecular Docking and Molecular Dynamics Simulations

Rashid, R. S. M., Temurlu, S., Abourajab, A., Karsili, P., Dinleyici, M., Al-Khateeb, B., & Icil, H. (2023) · Pharmaceuticals · doi:10.3390/ph16040555 · Cited by 16 · see citing works

Marine Sponge Cribrochalina vasculum Compounds Activate Intrinsic Apoptotic Signaling and Inhibit Growth Factor Signaling Cascades in Non–Small Cell Lung Carcinoma

Zovko, A., Viktorsson, K., Hååg, P., Kovalerchick, D., Färnegårdh, K., Alimonti, A., Ilan, M., Carmeli, S., & Lewensohn, R. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0329 · Cited by 16 · see citing works

Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice

Beumer, J. H., Franke, N. E., Tolboom, R., Buckle, T., Rosing, H., Lázaro, L. L., Schellens, J. H. M., Beijnen, J. H., & van Tellingen, O. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9234-8 · Cited by 14 · see citing works

The value of trabectedin in the treatment of soft tissue sarcoma

Nakamura, T., Matsumine, A., & Sudo, A. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s84789 · Cited by 14 · see citing works

NP04634 prevents cell damage caused by calcium overload and mitochondrial disruption in bovine chromaffin cells

Valero, T., del Barrio, L., Egea, J., Cañas, N., Martı́nez, A., Garcı́a, A. G., Villarroya, M., & López, M. G. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.02.021 · Cited by 13 · see citing works

A divergent strategy for synthesis of the tetrahydroisoquinoline alkaloids renieramycin G and a lemonomycin analog

MAGNUS, P. D., & Matthews, K. S. (2012) · Tetrahedron · doi:10.1016/j.tet.2012.02.043 · Cited by 12 · see citing works

Efficient dynamic kinetic resolution method for the synthesis of enantiopure 6-hydroxy- and 6-methoxy-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid

Forró, E., Megyesi, R., Paál, T. A., & Fülöp, F. (2016) · Tetrahedron Asymmetry · doi:10.1016/j.tetasy.2016.10.011 · Cited by 12 · see citing works

Hydrogen-Bonding Patterns of Minor Groove-Binder−DNA Complexes Reveal Criteria for Discovery of New Scaffolds

Spitzer, G. M., Wellenzohn, B., Markt, P., Kirchmair, J., Langer, T., & Liedl, K. R. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci800455f · Cited by 12 · see citing works

Marine Natural Products — a Vital Source of Novel Biotherapeutics

Begum, S. M. F. M., & Hemalatha, S. (2022) · Current Pharmacology Reports · doi:10.1007/s40495-022-00295-8 · Cited by 11 · see citing works

Navigating the paradox of senescence and chemoresistance in pancreatic cancer

Jeiroshi, A., Deng, J., Xu, Z., Comandatore, A., Xu, G., Glaviano, A., Morelli, L., Garajová, I., & Giovannetti, E. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.06.007 · Cited by 10 · see citing works

Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies

Thertulien, R., Manikhas, G., Dirix, L. Y., Vermorken, J. B., Park, K., Jain, M. M., Jiao, J. J., Natarajan, J., Parekh, T. V., Zannikos, P., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1697-6 · Cited by 9 · see citing works

Fatal hepatic and renal toxicity as a complication of trabectedin therapy for radiation-induced sarcoma

Pick, A. M., & Nystrom, K. K. (2009) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155209352821 · Cited by 9 · see citing works

Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function

Pardo, B., Salazar, R., Ciruelos, E., Cortés-Funes, H., García, M., Majem, M., Montés, A. F., Cuadra, C., Soto-Matos, A., Lebedinsky, C. A., et al. (2011) · Medical Oncology · doi:10.1007/s12032-011-9979-8 · Cited by 8 · see citing works

Recent advances in natural product-based anticancer agents

Negi, A. S., & Jain, S. (2022) · Studies in natural products chemistry · doi:10.1016/b978-0-323-91250-1.00010-0 · Cited by 8 · see citing works

Synthesis and antitumor activity evaluations of albumin-binding prodrugs of CC-1065 analog

Wang, Y., Jiang, J., Jiang, X., Cai, S., Han, H., Li, L., Tian, Z., Jiang, W., Zhang, Z., Xiao, Y., et al. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.05.025 · Cited by 8 · see citing works

The place of trabectedin in the treatment of soft tissue sarcoma: an umbrella review of the level one evidence

Andreeva-Gateva, P. A., & Chakar, S. (2019) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2019.1589449 · Cited by 8 · see citing works

Complete remission of a reccurrent mesenteric liposarcoma with rare histological features following the administration of trabectedin

Tsoukalas, N., Tolia, M., Lypas, G., Panopoulos, C. G., Barbounis, V., Koumakis, G., & Efremidis, A. P. (2013) · Oncology Letters · doi:10.3892/ol.2013.1646 · Cited by 7 · see citing works

Anti-cancer agents from natural sources: A review

Nerkar, A. G., Chakraborthy, G. S., & Ukirde, R. D. (2021) · Current Trends in Pharmacy and Pharmaceutical Chemistry · doi:10.18231/j.ctppc.2021.011 · Cited by 6 · see citing works

Naturally occurring, natural product inspired and synthetic heterocyclic anti-cancer drugs

Kaur, M., Kaur, M., Bandopadhyay, T., Sharma, A., Priya, A., Singh, R. A., & Banerjee, B. (2022) · Physical Sciences Reviews · doi:10.1515/psr-2022-0003 · Cited by 6 · see citing works

Combination of Trabectedin With Oxaliplatinum and 5-Fluorouracil Arrests a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model

Zhu, G., Zhao, M., Han, Q., TAN, Y., SUN, Y., Bouvet, M., Singh, S. R., Ye, J., & Hoffman, R. M. (2019) · Anticancer Research · doi:10.21873/anticanres.13805 · Cited by 6 · see citing works

Les alkylants

Abid, F. B., Gazzah, A., Ousbane, A., Gutierrez, M., & Brain, E. G. C. (2007) · ONCOLOGIE · doi:10.1007/s10269-007-0785-z · Cited by 5 · see citing works

Trifluoroacetic Acid-Mediated Oxidative Self-Condensation of Acetophenones in the Presence of SeO2: A Serendipitous Approach for the Synthesis of Fused [1,3]Dioxolo[4,5-d][1,3]dioxoles

Marpna, I. D., Shangpliang, O. R., Wanniang, K., Kshiar, B., Lipon, T. M., Laloo, B. M., & Myrboh, B. (2021) · ACS Omega · doi:10.1021/acsomega.1c01466 · Cited by 5 · see citing works

Changes in Neutrophil-to-lymphocyte Ratio Predict Efficacy of Trabectedin for Soft-tissue Sarcoma

Sato, Y., Nakano, K., Kawaguchi, K., Fukuda, N., Wang, X., Urasaki, T., Ohmoto, A., Hayashi, N., Yunokawa, M., Ono, M., et al. (2021) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10040 · Cited by 5 · see citing works

Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer

del Campo, J. M., Muñoz‐Couselo, E., de Corcuera, I. D., & Oaknin, A. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.59 · Cited by 5 · see citing works

A systematic and comprehensive review of the properties and synthesis of anticancer heterocyclic natural products

Chauhan, T., & Shah, M. (2025) · Current Pharmaceutical Analysis · doi:10.1016/j.cpan.2025.01.002 · Cited by 4 · see citing works

Pharmacophore modeling and virtual screening for the discovery of biologically active natural products

Badawy, M. E. I. (2020) · Studies in natural products chemistry · doi:10.1016/b978-0-12-817903-1.00011-5 · Cited by 4 · see citing works

Natural compounds and anticancer effects: The whole is greater than the sum of its parts

Martinotti, S., & Ranzato, E. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816151-7.00003-x · Cited by 4 · see citing works

Tubastrine, an antioxidant molecule from Tubastraea tagusensis sun coral, in the reversion of oxidative stress and neuron's death induced by Aβ42

da Silva, A. G., Rostirola, J. V. C., Speri, F. D., Pina, J. G., Kitahara, M. V., Longato, G. B., & Sciani, J. M. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70165 · Cited by 3 · see citing works

The Importance of Natural Products in Drug Discovery: Opportunities and Success

Nath, R., Nath, R., Mitra, A., Talukdar, A. D., Nath, D., Patra, J. K., Choudhury, M. D., & Kityania, S. (2024) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-97-4600-2_13 · Cited by 3 · see citing works

Treatment with trabectedin: should be indicated to all soft tissue sarcoma histotypes?

Grivas, A., Trafalis, D. T., Thanopoulou, E., Ziras, N., & Athanasiou, A. E. (2010) · PubMed · Cited by 3 · see citing works

Combination of Trabectedin With Irinotecan, Leucovorin and 5-Fluorouracil Arrests Primary Colorectal Cancer in an Imageable Patient-derived Orthotopic Xenograft Mouse Model

Zhu, G., Zhao, M. D., Han, Q., TAN, Y., Sun, Y., Bouvet, M., Clary, B. M., Singh, S. R., Ye, J., & Hoffman, R. M. (2019) · Anticancer Research · doi:10.21873/anticanres.13860 · Cited by 3 · see citing works

Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part II: Cell Cycle, DNA Damage Response, and Apoptosis Pathways

Miao, X., Koch, G., Shen, S., Wang, X., Li, J., Shen, X., Qu, J., Straubinger, R. M., & Jusko, W. J. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.10.036 · Cited by 3 · see citing works

Case Report of Suspected Rhabdomyolysis during Treatment with Trabectedin in a Patient with Metastatic Leiomyosarcoma

Lamm, W. W., Amann, G., & Brodowicz, T. (2010) · Case Reports in Oncology · doi:10.1159/000323261 · Cited by 2 · see citing works

In Vivo and Clinical Studies of Natural Products Targeting the Hallmarks of Cancer

Elbadawi, M., & Efferth, T. (2024) · Handbook of experimental pharmacology · doi:10.1007/164_2024_716 · Cited by 2 · see citing works

ABC Transporter Modulatory Drugs from Marine Sources: A New Approach to Overcome Drug Resistance in Cancer

Patel, A. S., Wang, D., Sim, H., Ambudkar, S. V., & Chen, Z. (2014) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-09801-2_8 · Cited by 2 · see citing works

P-gp Inhibitory Activity from Marine Sponges, Tunicates and Algae

Huang, X., Kumar, P., Anreddy, N., Xiao, X., Yang, D., & Chen, Z. (2014) · Springer eBooks · doi:10.1007/978-3-319-07145-9_28 · Cited by 2 · see citing works

Natural Product Screening

McKee, T. C., van Wyk, A. W. W., & Whitson, E. L. (2013) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4614-9135-4_3 · Cited by 2 · see citing works

Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project

Napoli, M. D., Pepa, C. D., Arenare, L., Scambia, G., Lorusso, D., Raspagliesi, F., Ferrandina, G., Salutari, V., Sorio, R., Mosconi, A. M., et al. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-016-3547-x · Cited by 1 · see citing works

Paradigm change in urological, gynaecological and breast cancer management: A new practice-changing data from ASCO 2022 annual meeting

Andrif, M., Elmarrachi, H., & Ismaili, N. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100677 · Cited by 1 · see citing works

Trabectedin and low-dose radiation therapy in patients with advanced leiomyosarcoma

Martín‐Broto, J., Olarte, A., Fernández, R., Ferreira, M., Carrasco-García, I., Gálvez-Montosa, F., Pérez, I. R., Peinado, J., Azinovic, I., Guzmán-Gómez, L. P., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231225044 · Cited by 1 · see citing works

Bioactive Metabolites Isolated from Microorganisms for Healthcare: Types and Delivery Routes

Mohanta, D., Maneesha, S., Ghangal, R., Solanki, M., & Patnaik, S. (2019) · Environmental chemistry for a sustainable world · doi:10.1007/978-3-030-04675-0_4 · Cited by 1 · see citing works

The role of Trabectedin as Second-Line Treatment of Advanced Soft Tissue Sarcoma: Update of Key Efficacy and Safety Data

Cesne, A. L. (2022) · Future Oncology · doi:10.2217/fon-2022-0516 · Cited by 1 · see citing works

Highlights of Natural Products in Prostate Cancer Drug Discovery

Salvador, J. A. R., & Vania, M. (2011) · InTech eBooks · doi:10.5772/27401

Arzneiverordnungen 2007 im Überblick

Schwabe, U. (2008) · Springer eBooks · doi:10.1007/978-3-540-69219-5_1

Management of Ovarian Cancer and Soft Tissue Sarcoma: Focus on Trabectedin

Dahl, K. D. C., Chan, T. W., Balkhi, E., & Zeineldin, R. (2011) · Clinical Medicine Reviews in Oncology · doi:10.4137/cmro.s1605

Exploring the Capabilities of Marine Metabolites

Majumdar, K., Verma, A. K., Kathpalia, K. V., Panja, A. S., & Prabhakar, P. K. (2024) · Advances in medical technologies and clinical practice book series · doi:10.4018/979-8-3693-5878-8.ch005

Trabectedin: A new therapeutic agent for soft tissue sarcoma

Ueda, T. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx569.003

Trabectedin (ET-743) from Marine Tunicate for Cancer Treatment

Atmaca, H., & Bozkurt, E. (2014) · Springer eBooks · doi:10.1007/978-3-319-07145-9_19 · Cited by 3 · see citing works

Trabectedin in Soft Tissue Sarcomas

Brodowicz, T. (2014) · Future Oncology · doi:10.2217/fon.14.117 · Cited by 26 · see citing works

Trabectedin as a New Chemotherapy Option in the Treatment of Relapsed Platinum Sensitive Ovarian Cancer

Monk, B. J., Dalton, H., Benjamin, I., & Tanovı́c, A. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802002814 · Cited by 33 · see citing works

Trabectedin (Yondelis ; ET-743) : a drug of marine origin for soft-tissue sarcomas

Schöffski, P., Floris, G., Wildiers, H. P. M. W., Stefan, C., Rogiers, A., & Dumez, H. (2008) · Cited by 2 · see citing works